.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX21_Tepotinib.Tepotinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX21_Tepotinib.Tepotinib| name: | Tepotinib |
| ATC code: | L01EX21 | route: | oral |
| n-compartments | 2 |
Tepotinib is a selective MET inhibitor used for the treatment of adult patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. It is an orally administered targeted therapy that inhibits the hepatocyte growth factor (HGF)/MET signaling pathway. Tepotinib is approved in several countries, including the United States and the European Union.
Pharmacokinetic parameters are reported for adult patients with advanced solid tumors and NSCLC after oral administration.
Xiong, W, et al., & Girard, P (2022). Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study. Cancer chemotherapy and pharmacology 89(5) 655–669. DOI:10.1007/s00280-022-04423-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35385993
Falchook, GS, et al., & Hong, DS (2020). First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 26(6) 1237–1246. DOI:10.1158/1078-0432.CCR-19-2860 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31822497
Shitara, K, et al., & Doi, T (2020). Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors. Japanese journal of clinical oncology 50(8) 859–866. DOI:10.1093/jjco/hyaa042 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32328660